GLP-1 Clinic Landscape Report 2026
The first comprehensive data analysis of GLP-1 weight loss clinic availability across the United States
Executive Summary
The GLP-1 medication market has experienced explosive growth since 2023, driven by the FDA approval and widespread adoption of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) for weight management. This report provides the first comprehensive analysis of clinic-level availability across the United States.
Our dataset encompasses 5,699 verified GLP-1 weight loss clinics across all 51 U.S. states and territories. Key findings include significant geographic variation in clinic density, emerging telehealth adoption patterns, and rapid market expansion in select metropolitan areas.
This report serves as a foundational resource for patients seeking GLP-1 treatment, healthcare investors evaluating market opportunities, and policymakers tracking access to obesity medicine.
Geographic Distribution
Top 25 States by Clinic Count
| Rank | State | Clinics | % of Total |
|---|---|---|---|
| 1 | FL | 83 | 1.5% |
| 2 | NJ | 63 | 1.1% |
| 3 | OH | 59 | 1.0% |
| 4 | CT | 56 | 1.0% |
| 5 | PA | 46 | 0.8% |
| 6 | VA | 42 | 0.7% |
| 7 | MO | 37 | 0.6% |
| 8 | TN | 37 | 0.6% |
| 9 | CA | 35 | 0.6% |
| 10 | MD | 34 | 0.6% |
| 11 | TX | 32 | 0.6% |
| 12 | MI | 31 | 0.5% |
| 13 | SC | 29 | 0.5% |
| 14 | NC | 28 | 0.5% |
| 15 | MA | 26 | 0.5% |
| 16 | OR | 23 | 0.4% |
| 17 | NY | 21 | 0.4% |
| 18 | NV | 18 | 0.3% |
| 19 | HI | 18 | 0.3% |
| 20 | UT | 18 | 0.3% |
| 21 | CO | 17 | 0.3% |
| 22 | KY | 17 | 0.3% |
| 23 | IN | 17 | 0.3% |
| 24 | GA | 16 | 0.3% |
| 25 | MN | 16 | 0.3% |
Note: Florida, New Jersey, and Ohio lead the nation in GLP-1 clinic density. However, per-capita analysis reveals that smaller states like Connecticut have higher clinic-to-population ratios.
Top 20 Metropolitan Areas
| Rank | City | Clinics |
|---|---|---|
| 1 | Newark, NJ | 34 |
| 2 | Stamford, CT | 33 |
| 3 | Orlando, FL | 30 |
| 4 | Baltimore, MD | 30 |
| 5 | Tampa, FL | 29 |
| 6 | Jersey City, NJ | 29 |
| 7 | Philadelphia, PA | 26 |
| 8 | St Louis, MO | 24 |
| 9 | Columbus, OH | 24 |
| 10 | Detroit, MI | 22 |
| 11 | Richmond, VA | 21 |
| 12 | Honolulu, HI | 18 |
| 13 | Cincinnati, OH | 17 |
| 14 | Greenville, SC | 16 |
| 15 | Portland, ME | 16 |
| 16 | Raleigh, NC | 15 |
| 17 | Wilmington, DE | 15 |
| 18 | Las Vegas, NV | 13 |
| 19 | Memphis, TN | 13 |
| 20 | Kansas City, MO | 13 |
Service Offerings
Telehealth Availability
130 of 5,699 clinics with telehealth data available
Telehealth adoption for GLP-1 prescribing remains in early stages, with only 24% of tracked clinics offering virtual consultations. This represents a significant opportunity for expansion, particularly in rural and underserved areas where in-person access is limited.
Medication Availability
Data Limitation: Medication-level tracking is an emerging area of our dataset. Most clinics offer both semaglutide and tirzepatide, but standardized reporting is still being established across providers.
Market Insights
Key Trends
- Urban Concentration: Major metropolitan areas show significantly higher clinic density, with Newark, Stamford, and Orlando leading the nation.
- Regional Variation: The Northeast and Southeast show higher adoption rates compared to Mountain and Plains states.
- Telehealth Gap: With only 24% of clinics offering virtual care, there is substantial room for growth in digital-first weight management programs.
- Market Maturity: The presence of 5,699+ clinics nationwide indicates a mature, competitive market with ongoing consolidation expected.
Implications for Patients
Access to GLP-1 medications varies significantly by geography. Patients in states like Florida, New Jersey, and Connecticut have dozens of clinic options, enabling price comparison and personalized care selection. In contrast, residents of less-served states may need to consider telehealth providers or travel to neighboring areas.
Looking Ahead
We expect continued expansion in 2026-2027, driven by:
- Broader insurance coverage for GLP-1 medications
- New market entrants (national chains, retail clinics, digital-first platforms)
- Regulatory clarity on compounding pharmacies and generic alternatives
- Integration with holistic weight management programs (nutrition, exercise, behavioral health)
Find a GLP-1 Clinic Near You
Browse our directory of 5,699+ verified clinics offering semaglutide and tirzepatide for weight loss.
Methodology
This report is based on data collected from 5,699 verified GLP-1 weight loss clinics across the United States as of March 2026. Data sources include:
- Public business directories and health provider registries
- Direct clinic submissions via our Get Listed platform
- Automated web scraping with manual verification
- Patient-contributed reviews and updates
All clinic data undergoes validation for accuracy. Telehealth and medication availability are self-reported by providers or inferred from public-facing websites. Geographic distribution is based on primary clinic locations.
Last Updated: March 23, 2026 | Next Update: June 2026
Questions or feedback? Contact our research team